PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-35.79%
Cash & equivalents declining -35.79% while AVXL's grows 23.77%. Howard Marks would question why our liquidity is shrinking while competitor builds cash.
No Data
No Data available this quarter, please select a different quarter.
-35.79%
Below half of AVXL's 23.77%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-31.27%
Higher Other Current Assets Growth compared to AVXL's zero value, indicating worse performance.
-32.53%
Below half of AVXL's 24.06%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
-2.15%
Both AVXL and the company show zero PP&E (Net) Growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-0.04%
Higher Other Non-Current Assets Growth compared to AVXL's zero value, indicating worse performance.
-1.56%
Both AVXL and the company show zero Total Non-Current Assets Growth.
No Data
No Data available this quarter, please select a different quarter.
-28.33%
Below half of AVXL's 24.06%. Michael Burry sees a potential red flag for stagnation or capital shortage.
-12.11%
Similar yoy growth to AVXL's -11.23%. Walter Schloss sees parallel payables strategy. Check top-line correlation.
-29.66%
Higher Short-Term Debt Growth compared to AVXL's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
6.29%
Higher Deferred Revenue (Current) Growth compared to AVXL's zero value, indicating better performance.
100.00%
Higher Other Current Liabilities Growth compared to AVXL's zero value, indicating worse performance.
-11.86%
Less than half of AVXL's 8.42%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Higher Other Non-Current Liabilities Growth compared to AVXL's zero value, indicating worse performance.
-7.08%
Less than half of AVXL's 54.08%. David Dodd sees a more conservative approach to non-current liabilities.
No Data
No Data available this quarter, please select a different quarter.
-11.32%
Less than half of AVXL's 8.42%. David Dodd sees far fewer liability expansions relative to competitor.
6.25%
50-75% of AVXL's 8.41%. Bruce Berkowitz notes minimal new equity relative to competitor.
-2.72%
0.5-0.75x AVXL's -4.94%. Martin Whitman is wary of weaker retention or lower profitability.
100.00%
Higher AOCI Growth compared to AVXL's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-46.50%
Below half AVXL's 27.95%. Michael Burry sees potential underperformance in building shareholder capital.
-28.33%
Below half AVXL's 24.06%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
-8.76%
Higher Total Debt Growth compared to AVXL's zero value, indicating worse performance.
40.72%
Less than half of AVXL's -23.77%. David Dodd sees better deleveraging or stronger cash buildup than competitor.